OrsoBio is developing first-in-class therapies that target energy metabolism pathways to treat severe metabolic disorders, including obesity, diabetes, and dyslipidemias. Their proprietary compounds, such as mitochondrial protonophores and ACC2 inhibitors, aim to enhance insulin sensitivity and increase energy expenditure, addressing the critical need for effective treatments in this high-morbidity area.
Funding
$166.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WPFounders
Product
Problem
Severe metabolic disorders, including obesity, diabetes, dyslipidemias, NASH, and lipodystrophies, present significant challenges due to their high morbidity and mortality rates. Current treatments often fail to address the underlying energy imbalances that contribute to these conditions, leaving a critical need for more effective therapies.
Solution
OrsoBio is developing first-in-class therapies targeting fundamental energy metabolism pathways to restore energy homeostasis and treat severe metabolic disorders. Their pipeline includes Acetyl-CoA Carboxylase 2 (ACC2) inhibitors to improve insulin sensitivity, Liver X Receptor (LXR) inverse agonists to improve plasma triglycerides and cholesterol levels, mitochondrial protonophores to increase energy expenditure, and ACMSD inhibitors to augment NAD+ biosynthesis and improve mitochondrial function. These compounds aim to address the root causes of metabolic dysfunction and prevent organ damage. By targeting key pathways relevant to maintaining energy balance, OrsoBio's therapies offer a novel approach to treating these complex conditions.
Target Audience
The primary target audience includes patients suffering from severe metabolic disorders such as obesity, type 2 diabetes, severe dyslipidemias, NASH, lipodystrophies, and those at risk of organ failure due to metabolic dysfunction.
Features
- TLC-3595: Selective ACC2 inhibitor for improving insulin sensitivity in patients with type 2 diabetes.
- TLC-2716: LXR inverse agonist for improving plasma triglycerides and cholesterol in patients with severe dyslipidemias and hepatic steatosis.
- TLC-6740, TLC-1180, and TLC-1235: Mitochondrial protonophores to increase energy expenditure and improve metabolic and cardiovascular health in patients with obesity and lipodystrophies.
- ACMSD inhibitor: Augments NAD+ biosynthesis and improves mitochondrial function in patients with liver and/or kidney dysfunction.